KINDERHOOK, N.Y. – June 24, 2012 – American Bio Medica Corporation (ABMC.PK) announces that the United States Patent & Trademark office has granted a patent to the Company for its all inclusive urine point of collection drug test cup product lines, the Rapid TOX Cup II and the RDS® InCup, U.S. Patent Number 8,206,661 covers the Company’s all-inclusive cup product line and relates to an assay device for the testing of liquid samples for determining the presence of undesirable constituents, more particularly to a test device having a transparent container for retaining a liquid sample and test strips within the container for indicating visually the presence of particular drugs of abuse.

The Company’s Rapid TOX Cup II and InCup product lines are well received in the Company’s core markets of workplace and government. The Rapid TOX Cup II is used by a number of statewide criminal justice agencies and given its cost-effectiveness and use of use.

With these grants, ABMC’s intellectual property portfolio for its drug of abuse testing line increases to 14 United States patents and 15 foreign patents, in addition to a number of pending patent applications both within the US and internationally.

For more information on American Bio Medica Corporation or its products, please visit

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay test kits, including some of the world’s most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to “penny stock” rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2010, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company’s common shares.

American Bio Medica Corporation
Stan Cipkowski, 800-227-1243, Ext 106
Chief Executive Officer